Equities research analysts at Oppenheimer Holdings Inc. assumed coverage on shares of TherapeuticsMD Inc (AMEX:TXMD) in a report released on Tuesday. The brokerage set an “outperform” rating on the stock.

Shares of TherapeuticsMD (AMEX:TXMD) traded up 2.30% on Tuesday, reaching $7.12. 2,246,747 shares of the company’s stock were exchanged. The company’s 50 day moving average price is $6.24 and its 200-day moving average price is $7.35. The stock’s market cap is $1.40 billion. TherapeuticsMD has a 52-week low of $4.39 and a 52-week high of $11.26.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

Receive News & Stock Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related stocks with our FREE daily email newsletter.